LOS ANGELES, Dec. 11, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nutex Health Inc. ("Nutex" or "the Company") (NASDAQ: NUTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Nutex is the subject of a report published by Blue Orca Capital on July 22, 2025 ...

Core Viewpoint - Nutex Health Inc. has announced an extension of its stock repurchase program, reflecting the Board's confidence in the company's long-term strategy and commitment to enhancing shareholder value [1][5]. Group 1: Stock Repurchase Program - The original stock repurchase program, announced on August 14, 2025, authorized the repurchase of up to $25.0 million of common stock over a six-month period starting from the filing of the Form 10-Q for the quarter ended June 30, 2025 [2]. - The program has been extended through March 31, 2026, and will be implemented under Rule 10b-18 and a Rule 10b5-1 trading plan, effective around December 4, 2025 [3]. - The purpose of the share repurchase program is to increase shareholder value and offset dilution from additional shares related to stock compensation obligations for under-construction and ramping hospitals [4]. Group 2: Company Overview - Nutex Health Inc., headquartered in Houston, Texas, was founded in 2011 and operates as a healthcare management and operations company with two divisions: Hospital Division and Population Health Management Division [6]. - The Hospital Division owns and operates 25 facilities across 11 states, focusing on innovative healthcare models, including micro-hospitals and specialty hospitals [6]. - The Population Health Management Division operates provider networks such as Independent Physician Associations and provides management and administrative support services to affiliated hospitals and physician groups [7].

Core Insights - Nutex Health held a combined earnings call for the Second and Third Quarter of 2025 to discuss financial performance and future plans [2][3] Financial Performance - The call included insights from key leaders, including the Chairman and CEO, CFO, and President, highlighting the company's financial results and operational progress [3] Strategic Direction - The company introduced its new Chief Operating Officer, Wesley Bamburg, indicating a focus on leadership and operational strategy moving forward [3]

Nutex Health (NasdaqCM:NUTX) Q3 2025 Earnings Call December 02, 2025 10:30 AM ET Company ParticipantsJon Bates - CFOJennifer Rodriguez - Head of Investor RelationsWarren Hosseinion - PresidentWes Bamberg - CEOTom Vo - CEOConference Call ParticipantsAnthony Vendetti - AnalystBradford Seagraves - AnalystGene Mannheimer - AnalystBill Sutherland - AnalystCarl Burns - AnalystOperatorGreetings and welcome to the Nutex Health 2Q and 3Q 2025 Financial Results Conference call. At this time, all participants are in a ...

Nutex Health (NasdaqCM:NUTX) Q3 2025 Earnings Call December 02, 2025 10:30 AM ET Company ParticipantsJon Bates - CFOJennifer Rodriguez - Head of Investor RelationsWarren Hosseinion - PresidentWes Bamberg - CEOTom Vo - CEOConference Call ParticipantsAnthony Vendetti - AnalystBradford Seagraves - AnalystGene Mannheimer - AnalystBill Sutherland - AnalystCarl Burns - AnalystOperatorGreetings and welcome to the Nutex Health 2Q and 3Q 2025 Financial Results Conference call. At this time, all participants are in a ...

Nutex Health (NasdaqCM:NUTX) Q3 2025 Earnings Call December 02, 2025 10:30 AM ET Speaker1Greetings and welcome to the Nutex Health 2Q and 3Q 2025 Financial Results Conference call. At this time, all participants are in a listen-only mode. Our question-and-answer session will follow the formal presentation. If anyone should require operator assistance, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce Jennifer Rodriguez of In ...

Core Insights - Nutex Health Inc. (NUTX) has experienced a successful year in stock performance and financial improvements, primarily due to arbitration wins [1] Company Overview - Nutex Health Inc. operates in healthcare management and operations [1] Financial Performance - The company has shown significant financial improvements over the past year, attributed to successful arbitration outcomes [1]

Core Viewpoint - Nutex Health Inc. is addressing a short seller report from Capybara Research, which appears to be an attempt to create market confusion and profit from a decline in the company's trading price [2][3]. Company Overview - Nutex Health Inc. is headquartered in Houston, Texas, and was founded in 2011. It operates in the healthcare management sector with two main divisions: Hospital Division and Population Health Management Division [4]. - The Hospital Division owns and operates 24 facilities across 11 states, focusing on innovative healthcare models such as micro-hospitals and specialty hospitals [4]. - The Population Health Management Division manages provider networks, including Independent Physician Associations (IPAs), and offers management and administrative support services to affiliated hospitals and physician groups [5].

Accessibility StatementSkip Navigation HOUSTON, Nov. 24, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 25 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks, today announced the reopening of Red River ER & Hospital in Sherman, Texas. "Sherman, Texas is a dynamic, fast-growing city on the Texas / Oklahom ...

Core Insights - Several stocks experienced significant movements in after-hours trading, influenced by earnings announcements and financing updates, particularly in the healthcare and biotech sectors [1] Company Summaries - **PACS Group Inc. (PACS)**: The stock surged 45.48% to $24.48 after a 16.63% increase during regular trading, closing at $16.83. The company reported Q3 net income of $52.4 million ($0.32 per share), up from $15.6 million ($0.10 per share) a year ago. Revenue increased to $1.345 billion from $1.026 billion. For fiscal 2025, PACS expects revenue between $5.25 billion and $5.35 billion, with adjusted EBITDA projected at $480 million to $490 million [2] - **Zynex, Inc. (ZYXI)**: The stock rose 4.49% after hours to $0.58, following a 32.14% gain during regular trading. The company reported a net loss of $42.9 million ($1.42 per share) for the quarter ended September 30, 2025, compared to a net income of $2.3 million ($0.07 per share) in the same period last year. Net revenue fell to $13.4 million from $50.0 million [3] - **Genenta Science S.p.A. (GNTA)**: The stock increased 7.34% after hours to $1.90, recovering from an 11.06% decline to $1.77. Last month, the company announced a securities purchase agreement for 4,285,715 American Depositary Shares at $3.50 per ADS, raising approximately $15.0 million before fees and expenses [4] - **Ekso Bionics Holdings, Inc. (EKSO)**: The stock gained 4.22% in after-hours trading to $4.20, after closing at $4.03, down 3.47% earlier in the day. In late October, the company disclosed a registered direct offering of 769,490 shares priced at $4.81 per share [5] - **Nutex Health Inc. (NUTX)**: The stock advanced 9.64% after hours to $123.00, following a 13.09% rise during regular trading to $112.19. The company reported Q3 net income of $55.4 million, reversing a net loss of $8.8 million in the same period last year. Revenue climbed to $267.8 million, up from $78.8 million, marking a 239.9% increase [6]